Standards, Options et Recommandations pour le traitement périopératoire des patients atteints d’un cancer bronchique non à petites cellules résécable d’emblée, opérables (mise à jour), rapport abrégé
详细信息 查看全文
- 作者：Benjamin Besse (1)
Alain Depierre (2)
Sylvie Guillo (3)
Clotilde Séblain-El Guerche (4)
Jean-Yves Douillard (5)
Annie Giniès
Christophe Hennequin (6)
Cécile Le Péchoux (7)
Bernard Milleron (8)
Denis Moro-Sibilot (9)
Pierre Mouillefarine (10)
élisabeth Quoix (11)
Jean-Fran?ois Régnard (12)
Marc Riquet (13)
Fabien Vaylet (14)
Gérard Zalcman (15) - 关键词：Carcinome pulmonaire non à petites cellules ; Chimiothérapie adjuvante ; Radiothérapie adjuvante ; Traitement néoadjuvant ; Recommandation pour la pratique clinique ; Carcinoma ; Nonsmall ; cell lung ; Chemotherapy adjuvant ; Radiotherapy adjuvant ; Neoadjuvant therapy ; Practice guidelines
- 刊名：Oncologie
- 出版年：2007
- 出版时间：November 2007
- 年：2007
- 卷：9
- 期：11
- 页码：800-809
- 全文大小：210KB
- 参考文献：1. Berghmans T, Paesmans M, Meert AP, et al. (2005) Survival improvement in resectable non-small cell lung cancer with neoadjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49: 13-3 CrossRef
2. Cancer Care Ontario (2005) Postoperative adjuvant chemotherapy, with or without radiotherapy, in completely resected non-small-cell lung cancer: a clinical practice guideline. Available: URL: http://www.cancercare.on.ca/pdf/pebc7-1-2s.pdf
3. Cancer Care Ontario (2005) Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline. Available: URL: http://www.cancercare.on.ca/pdf/pebc7-1-2f.pdf
4. Depierre A, Lagrange JL, Theobald S, et al. (2002) Cancer bronchopulmonaire non à petites cellules. John Libbey EUROTEXT, Paris
5. Depierre A, Milleron B, Moro-Sibilot D, et al. (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small-cell lung cancer. J Clin Oncol 20: 247-3 CrossRef
6. Douillard JY, Rosell R, De LM, et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7: 719-7 CrossRef
7. Fervers B, Hardy J, Philip T (2001) “Standards, Options and Recommendations- Clinical Practice Guidelines for cancer care from the French National Federation of Cancer Centres (FNCLCC). Br J Cancer 84: 1-2 CrossRef
8. Nagai K, Tsuchiya R, Mori T, et al. (2003) A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125: 254-0 CrossRef
9. Pignon JP, Tribodet H, Scagliotti GV, et al. (2006) Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomised controlled trials including 4584 patients. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol. 24, Abstract 7008
10. PORT Meta-analysis Trialists Group (2005) Postoperative radiotherapy for non-small-cell lung cancer. Cochrane Database Syst Rev: CD002142
11. Roselli M, Mariotti S, Ferroni P, et al. (2006) Postsurgical chemotherapy in stage IB non-small-cell lung cancer: Long-term survival in a randomized study. Int J Cancer 119: 955-0 CrossRef
12. Strauss GM, Herndon J, Maddaus MA, et al. (2006) Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia group B (CALGB) protocol 9633. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 24, Abstract 7007
13. The AGREE Collaboration (2003) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12: 18-3 CrossRef
14. Trodella L, Granone P, Valente S, et al. (2002) Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol 62: 11- CrossRef - 作者单位：Benjamin Besse (1)
Alain Depierre (2)
Sylvie Guillo (3)
Clotilde Séblain-El Guerche (4)
Jean-Yves Douillard (5)
Annie Giniès
Christophe Hennequin (6)
Cécile Le Péchoux (7)
Bernard Milleron (8)
Denis Moro-Sibilot (9)
Pierre Mouillefarine (10)
élisabeth Quoix (11)
Jean-Fran?ois Régnard (12)
Marc Riquet (13)
Fabien Vaylet (14)
Gérard Zalcman (15)
1. oncologue médical, institut Gustave-Roussy, Villejuif, France
2. pneumologue, CHU de Franche-Comté, Besan?on, France
3. FNCLCC, Paris, France
4. FNCLCC, Paris, France
5. oncologue médical, centre René-Gauducheau, Saint-Herblain, France
6. oncologue radiothérapeute, h?pital Saint-Louis, Paris, France
7. oncologue radiothérapeute, institut Gustave-Roussy, Villejuif, France
8. h?pital Tenon, Paris, France
9. CHU de Grenoble, Grenoble, France
10. Ligue nationale contre le cancer, Paris, France
11. CHRU de Strasbourg, Strasbourg, France
12. H?tel-Dieu, Paris, France
13. h?pital européen Georges-Pompidou, Paris, France
14. h?pital d’instruction des armées Percy, Clamart, France
15. CHU de Caen, Paris, France
文摘
Introduction An update of the Sor Clinical Practice Guidelines (CPG) for the perioperative treatment of operable patients with resecable non-small cell lung cancer, operable has been initiated by the French National Federation of Cancer Centres (FNCLCC). This work was performed in collaboration with the French Intergroup for Thoracic Oncology (IFCT), the French-speaking Language Society of Pneumology (SPLF), specialists from university or general hospitals and private clinics, and with the French National Cancer Institute. It is based on the methodology developed and used in the “Standards, Options and Recommendations-programme. This article presents a short version of the updated 2007 recommendations. Methods The guideline development process is based on literature review and critical appraisal by amultidisciplinary group of experts. The methodological approach combines systematic review with expert judgement. Recommendations take into account the effectiveness and toxicity of the different therapeutic alternatives and the levels of evidence. Following their development and prior to publication, independent practitioners in cancer care delivery reviewed SOR-guidelines. Results Therapeutic standards and options concerning adjuvant or neoadjuvant chemotherapy as well as adjuvant radiotherapy have been defined per stage (IA, IB, II and IIIA). Specific chemotherapy regimens have also been recommended. Conclusions After critical appraisal, the literature data appeared sufficient to update the recommendations validated in 2000. The literature will be searched and reexamined in 2008 within SOR’s systematic monitoring.